A simple, specific, accurate and precise reverse phase high pressure liquid chromatographic method has been developed for the simultaneous determination of paracetamol and lornoxicam from tablets and characterization of degradation products of lornoxicam by reverse phase C18 column (Inertsil ODS 3V C-18, 2504.6 mm, 5 μm). The sample was analyzed using buffer (0.02504 M):methanol in the ratio of 45:55, as a mobile phase at a flow rate of 1.5 mL/min and detection at 290 nm. The retention time for paracetamol and lornoxicam was found to be 2.45 and 9.40 min, respectively. The method can be used for estimation of the combination of these drugs in tablets. The method was validated as per ICH guidelines. The linearity of the developed method was achieved in the range of 249.09 -747.29 μg/mL (r 2 = 0.9999) for paracetamol and 4.0125-12.0375 μg/mL (r 2 = 0.9999) for lornoxicam. Recoveries from tablets were between 98 and 102%. The method was validated with respect to linearity, accuracy, precision, robustness and forced degradation studies which further proved the stability-indicating power. During the forced degradation studies, lornoxicam was observed to be labile to alkaline hydrolytic stress and oxidative stress (in the solution form). However, it was stable to the acid hydrolytic, photolytic and thermal stress (in both solid and solution form). The formed degraded products were investigated by electrospray ionization (ESI) time-of-flight mass spectrometry, NMR and IR spectroscopy. A possible degradation pathway was outlined based on the results. The method was found to be sensitive with a detection limit of 0.193 and 2.768 μg/ml, and a quantitation limit of 0.638 and 9.137 μg/ml for lornoxicam and paracetamol, respectively. Due to these attributes, the proposed method could be used for routine quality control analysis of these drugs in combined dosage forms.
cedure which affords specific determination of a drug substance in the presence of its degradation products" [2] . According to the International Conference on Harmonization (ICH) Guideline Q1A (R2) on the stability testing of new drug substances and products, the stability testing of the drug substance should be carried out under different stress conditions to validate the stability indicating supremacy of the analytical methods used for the analysis of stability samples [3] . The prime objective of studying the stability of a drug is to determine the shelf-life of the drug. Identification of the degradation products, establishment of degradation pathways and determination of intrinsic stability of the drug molecules and validation of the analytical procedure are the goals achieved by stress testing [3] . The various conditions specified for the forced degradation studies should include extremes of pH, oxidative, photolytic degradation, and the effect of temperature [4] [5] [6] [7] [8] [9] . In addition, the need for the stability studies on a drug candidate arises from the fact that the chemical integrity of the drug substance should be maintained until the compound is delivered to the intended site of action. Furthermore, a stability indicating assay method provides assurance on detection changes in identity as well as purity potency of the product.
Lornoxicam belongs to the non-steroidal antiinflammatory drug (NSAID) category [10] . Lornoxicam is a compound in the same chemical class as piroxicam, meloxicam and tenoxicam, with potent antiinflammatory, antipyretic and analgesic activity [11] . It works by blocking the action of cyclooxygenase which is responsible for the production of prostaglandin in the body.
Paracetamol is an analgesic and antipyretic. It is used in the treatment of pain and also for reducing Lornoxicam is chemically ((3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno [2,3- Literature review revealed that lornoxicam is not official in any pharmacopoeia. Upon a detailed literature survey, it was found that only a few selected RP-HPLC, LC and LC/MS/MS methods were reported for estimation of lornoxicam [13, 14] and paracetamol [15] [16] [17] in their individual and combined dosage form [18] and plasma samples. These methods are not so specific for simultaneous estimation of lornoxicam and paracetamol in their combined dosage form. To date, no method has been reported in the literature for the determination of lornoxicam along with characterization of its degradation products. Therefore, an improved method for the quantitative determination of lornoxicam and paracetamol is needed and also required to meet the stability-indicating demand. This is the first report of an RP-HPLC method for the estimation of lornoxicam and paracetamol in combined dosage form. The method was validated as per ICH guidelines [19] .
A stability study of lornoxicam towards acidic, alkaline, neutral, thermal, oxidative, and photolytic degradation processes was carried out, specified as per the ICH guidelines for stress testing. The aim of this work was to develop a stability indicating method for the determination of lornoxicam and also to characterize its degradation products using RP-HPLC. TOF/MS with electrospray ionization (ESI) interface in positive ion mode, NMR and IR spectroscopy were used for the identification and characterization of the drug and its degraded products.
EXPERIMENTAL Materials
Lornoxicam, active pharmaceutical ingredient (API), and working standard was supplied by Glenmark Generics Limited. Paracetamol, API, and working standard was supplied by Sri Krishna Pharmaceuticals Limited. Combination drug product of lornoxicam and paracetamol was provided by Zydus Cadila Healthcare Limited (Ahmedabad, India).
HPLC Conditions and standard solutions
The HPLC system (Shimadzu LC 2010C) consisted of a system controller (CLASS -VP) with PDA detector. An Inertsil ODS 3V C-18, 5μm (2504.6 mm) column was employed for the separation of impurities from lornoxicam. The column eluent was monitored at 290 nm. The mobile phase was prepared by mixing methanol and ammonium dihydrogen orthophosphate buffer (0.02504 molar and pH 7.3) in a ratio 55:45 (v/v). The flow rate was 1.5 ml/min. All determinations were performed at 30 C. All the samples were analyzed by HPLC method after filtration using 0.45 μm membrane filters. The injection volume was 20 μl.
For the preparation of lornoxicam and paracetamol mixed standard solution, accurately weighed 32 mg of lornoxicam powder was transferred to a 200 ml volumetric flask; then 150 ml of mobile phase was added and the mixture was sonicated and volume was made up to mark to prepare stock solution of lornoxicam. Then 50 mg of paracetamol working standard was transferred to a 100 ml volumetric flask, to this 50 ml of mobile phase was added and the mixture was sonicated. Then 5 ml of stock solution of lornoxicam was added to this 100 ml volumetric flask and the mixture was then sonicated. Volume was made up to mark with mobile phase to obtain final standard concentration of lornoxicam 8 µg/ml and paracetamol 500 µg/ml.
Mass spectrometry
Initial LC/MS/MS analysis was performed on LCQ Fleet and TSQ Quantum Access Mass Spectrometer. The analysis was performed in positive and negative ionization mode with electrospray ionization. The parameters for the ion source (voltage, IS, 5500 V, declustering potential, DP, 70 V, focusing potential, FP, 400 V and entrance potential, EP, 10 V) were set with nebulizer gas as air at a pressure of 40 psi and curtain gas as nitrogen at a pressure of 25 psi in mass spectrometer. An Inertsil ODS-3V C 18 column (2504.6 mm, 5 µm, GL Sciences, Japan) was used for the separation. The mobile phase was a mixture of methanol and ammonium dihydrogen orthophosphate buffer (pH 7.3 adjusted with triethylamine) in a ratio of 55:45 (v/v). The analysis was performed at a flow rate of 1.5 mL/min. (4.0, 6.4, 8 .0, 9.6 and 12.0 µg/ml) drug solution in mobile phase was used. The peak area of each concentration was plotted against the corresponding concentration to obtain the calibration graph and the plots were subjected to linear regression analysis.
NMR

Precision
Precision study was performed for the determination of method and intermediate precision (ruggedness). Method precision studies were performed by injecting same concentrations of paracetamol and lornoxicam i.e., 500 and 8 μg/ml, respectively, in hexplicate on the same day with same condition. While for intermediate precision studies; these concentrations were injected in hexplicate on different day by a different analyst, using a different HPLC system & different column lot using same lot of sample. Drug concentrations were calculated using the area obtained from the linearity plots and the results are expressed as percent relative standard deviation (RSD).
Limit of quantitation (LOQ) and limit of detection (LOD) LOQ and LOD were calculated using equation LOD = 3.3N/B and LOQ = 10N/B, where N is the standard deviation of the peak areas of the drugs (n = 3), taken as a measure of noise, and B is the slope of the corresponding calibration curve. LOD and LOQ of the target sample were determined by injecting each concentration in hexplicate. Solutions of paracetamol and lornoxicam were prepared at LOD and LOQ levels, corresponding to 0.03 (2.768 and 0.193 μg/ml for paracetamol and lornoxicam, respectively) and 0.1% (9.137 and 0.638 µg/ml), respectively.
System suitability tests
System suitability test parameters must be checked to ensure that the system is working correctly during the analysis. The test parameters such as capacity factor, selectivity factor, resolution, number of theoretical plates (column efficiency) and symmetry factor were checked.
Recovery studies
The accuracy of the method was evaluated at 50, 100 and 150% of nominal concentration for paracetamol and lornoxicam. At each level of the amount, six determinations were performed in order to check the recovery of the drug at different levels in the formulations.
Specificity
Specificity is the ability of the method to measure the analyte response in the presence of its potential impurities [3] . The method specificity and stability-indicating of the analytical method were evaluated by the ability of the chromatographic conditions to separate the major degradation products from paracetamol and lornoxicam and by determination of the purity of the drug peak in the presence of placebo (synthetic blend of tablet excipients), mobile phase, blank using a PDA detector. Peak purity of the para-cetamol and lornoxicam in stressed samples was verified using the PDA in the wavelength range of 200-400 nm.
Robustness of the method
The robustness of the method was evaluated during development by making small, but deliberate, changes to the method parameters. In addition, experimental conditions were purposely altered and the resolution between paracetamol and lornoxicam was evaluated. To study the effect of flow rate and column temperature on the resolution, these were changed by 0.2 units from 1.3 to 1.7 ml/min and from 35 to 45 C, respectively. The mobile phase components ratio was changed by 2% (i.e., 57:43 and 53:47) and pH of mobile phase was changed by 0.2 (pH 7.1 and 7.5).
Stability
The combined standard solution of paracetamol and lornoxicam was stored at two different conditions (room temperature and 8 C), unprotected from light, at ambient conditions and assayed after initial, 2, 4, 7, 13, 19 and 25 h against a freshly prepared standard solution.
Analysis of paracetamol and lornoxicam in prepared formulation
To determine the concentration of paracetamol and lornoxicam in tablets (labeled claim: 500 and 8 mg per tablet), 20 intact tablets were accurately weighed and the average weight was calculated. The tablets were crushed into a fine powder. An accurately weighed quantity of powder equivalent to 16 mg of lornoxicam was transferred into a 200 ml volumetric flask. Then, 150 ml of diluent was added to the flask and sonicated for 30 min with intermittent shaking. The volume was made up to the mark and mixed. The solution was then filtered through a 0.45 µm PVDF filter. 5.0 ml of filtrate was transferred into a 50 ml volumetric flask and the diluent was added up to the mark to get a final concentration of 500 µg/ml of paracetamol and 8 µg/ml of lornoxicam.
Preparation of degradation products of lornoxicam
Different stress conditions for the forced degradation studies of bulk drug and pharmaceutical formulations were used. Zero time samples and placebos, i.e., samples without drug with other excipients, were also prepared and analyzed for the comparison with the stressed samples. The chromatograms of the blank solutions consisting of stress agents with and without the drug and the zero time drug solutions together with stress agents were inspected in order to mark the peaks corresponding to stress agents and to distinguish them from the potential drug degradation products. The stressed samples were also detected under different wavelengths in order to ensure that no additional degradation product(s) were formed with different wavelength values as compared to lornoxicam. The total chromatographic run time was 2.5 times longer than the retention time of the drug peak.
Acidic conditions
For acidic hydrolysis, hydrochloric acid of different strengths was used for the preparation of ion. First, 100 mg of lornoxicam in 100 ml volumetric flask was dissolved in 5 ml 0.01 N HCl and kept at 25 C for 2 h, at 40 C for 8 h and at 80 C for 4 h, and then volume was made up with 95 ml of mobile phase. Then, the drug solutions were prepared similarly in 1, 2 and 5 M HCl and kept at 80 C for 4 h.
Alkaline conditions
Alkaline degradation studies were performed by preparing 1 mg/ml lornoxicam solution. First, 100 mg of lornoxicam in 100 ml volumetric flask was dissolved in 5 ml 0.01 M sodium hydroxide and kept at 25 C for 2 h, at 40 C for 8 h and at 80 C for 4 h, and then volume was made up with 95 ml of mobile phase. Then, the drug solutions prepared in 5 M NaOH were kept similarly at 40 C for 8 h and at 80 C for 4 h. Identification of the degradation product was done after alkaline hydrolysis of drug solution to complete degradation.
Subsequently, after complete degradation, the pH of the solution was adjusted to precipitate the degraded product of lornoxicam. The precipitates were filtered, washed and dried under vacuum and protected from air and light.
Neutral (water) conditions
For neutral hydrolysis, 100 mg of lornoxicam in 100 ml volumetric flask was dissolved in 5 ml water and exposed to different temperature conditions: 25 C for 2 h, 40 C for 8 h, 80 C for 4 h, and then the volume was made up with 95 ml of water (1 mg/ml).
Thermal degradation studies
To investigate the susceptibility of the drug under thermal stress conditions, the bulk drug was spread in a thin layer in a Petri plate, and the drug solution (1 mg/ml in 0.01 M HCl) was exposed to dry heat in a hot air oven at 70 C for 15 days. For the identification, purification and analysis of major degradation product after thermal degradation, the solvent was exposed to freeze drying and protected from air and light.
Oxidative conditions
Oxidative degradation studies were performed using hydrogen peroxide solution of different strengths at room temperature. The lornoxicam solution (1 mg/ml) was first dissolved in 5 ml 3% H 2 
The identification and analysis of the degraded products was done by IR, NMR and MS/ESI.
Photodegradation studies
Photodegradation studies were carried out by exposing the drug solutions (1 mg/ml in 0.1 M HCl, water: methanol mixture and 0.1 M NaOH) as well as powder drug in a photostability chamber. The powder was spread as a thin layer in a Petri plate. The overall illumination at the point of placement was 6000 lx fluorescent and 0. Table 1 . Table 1 Precision
The RSD value was found to be in the range of 1.5-0.8% for paracetamol and lornoxicam, respectively, for intraday (method) precision studies, whereas the RSD values ranged 0.5-0.3% for paracetamol and lornoxicam, respectively, for inter-day (intermediate) precision studies. All data indicate that the method is highly precise for the determination of paracetamol and lornoxicam (Table 1) .
LOD and LOQ
For the LOD solution, the mean response of the 6 injections minus 3.3 times the standard deviation was greater than zero. For the LOQ solution, the mean response of the 6 injections minus 10 times the standard deviation was also found to be greater than zero [20] . Thus, the signal-to-noise levels meet the ICH requirements for LOD and LOQ limits ( Table 2 ).
System suitability tests
The system suitability tests parameters like the capacity factor, retention time for separation of each product and the number of theoretical plates for each compound is presented in Table 3 and was within the desired limits. The calculated value for the tailing factor for each compound (acceptable range of 0.8 ≤ T ≤ 1.5) [21, 22] is also shown in Table 3 .
Recovery studies
The proposed method when used for subsequent estimation of paracetamol and lornoxicam from pharmaceutical dosage forms after spiking with 50, 100 and 150% of additional drug afforded recovery of 99-102% for paracetamol and 98-101% for lornoxicam as listed in Tables 4 and 5 . The data of summary of validation parameters are also listed in Tables 4  and 5 . All data indicated that the method is highly accurate for the determination of paracetamol and lornoxicam and its degraded samples without any interference.
Specificity
The specificity of the HPLC method is illustrated in Table 6 where complete separation of paracetamol and lornoxicam from its placebo, diluent (mobile phase) and blank can be noticed. In addition, it was also determined that the paracetamol and lornoxicam peak was spectrally pure and no degradation product peak was detected as co-elute with paracetamol and lornoxicam. Studies performed showed the 3-point peak purity value of 0.9979 for lornoxicam and value of 0.9997 for paracetamol. As the 3-point peak purity value was significantly more than 0.9950, the method was concluded to be specific for the analysis of paracetamol and lornoxicam in pharmaceutical formulations.
Robustness of the method
The standard deviation of peak areas was calculated for each parameter and RSD was found to be less than 2%. The low values of RSD shown in Table   7 indicate the robustness of the method. 
Stability of analytical solution
The solution stability was checked for the sample preparation and standard preparation for 25 h. The results obtained were well within the acceptance criteria. Therefore, the standard preparation and sample preparation were stable in solution form for 25 h at room temperature. It was found that the change in area was negligible, which shows that the drug solution of standard and sample remained stable.
Analysis of prepared formulation
The peaks of RT at 9.0 and 2.4 min were observed in chromatogram of the paracetamol and lornoxicam samples extracted from tablets. There was no interference from the excipients commonly present in the tablets. The paracetamol and lornoxicam content was found to be 100.7% with a RSD of 0.8 and 101.7% with a RSD of 1.5. It may therefore be inferred that degradation of paracetamol and lornoxicam had not occurred in the formulation that was analysed by this method. The low RSD value indicated the suitability of this method for routine analysis of paracetamol and lornoxicam in pharmaceutical dosage forms.
Identification of degradation products of lornoxicam
The lornoxicam was found to be susceptible to alkaline hydrolytic and oxidative stress (in solution form), but it was stable to the acid hydrolytic, photolytic stress (in both solid and solution form) and the thermal stress (in solid form). Table 8 shows the summary of results from forced degradation studies of lornoxicam and the percentage of lornoxicam remained the same after undergoing stress. The chemical structure of lornoxicam was studied and shown that there were sites leading to the formation of degraded products as shown in Figure 4 . The chromatogram of samples degraded with hydrogen peroxide and alkaline hydrolysis showed a well-separated peak of pure lornoxicam as well as some additional peaks at different RT values. The peaks of degraded product were well resolved from the drug peak as shown in Figures  5 and 6 .
The MS/ESI using selected ion monitoring in the positive ion mode provided a highly selective method for the determination and characterization of lornoxicam and its degradation products, respectively. At the optimum conditions described in the experimental section, the ESI of lornoxicam were identified at mass-to-charge ratio (m/z) 371.81, corresponding to Figures 7 and 8 show the peroxide degraded product NMR and ion mass spectra. Figure 9 shows the IR spectra of peroxide degraded product ion.
Acidic conditions
The drug was found to be stable to the acidic hydrolysis without any reduction in the drug peak area. No degradation of the drug was observed in 0.01 N HCl on heating initially at 25 C for 30 min and then for 2 h, in 2 M HCl at 80 C for 2 and 4 h and in 5 M HCl at 80 C for 2 h and then for 4 h. Very little degradation was observed on exposing to 5 M HCl for 4 h (Table 8 ). 
Alkaline conditions
The drug was found to be alkali labile. The amount of drug remaining after heating for 2 h at 25 C in 5 M NaOH was 93.25%. In order to study the effect of stress condition heating for 4 h at 80 C in 5 M NaOH was carried out with 17.10% of drug degradation. The HPLC analysis indicated the presence of a degraded product peak with the reduction in the area of the drug peak ( Figure 7) . The peak at RT 2.617 min was found to be of major degradation pro-duct after heating for 2 h as well as for 4 h in 5 M NaOH. The shorter retention time of degraded product indicates different polarity or lower molecular mass as compare to lornoxicam. For milder conditions the drug showed no degradation.
Oxidative conditions
The drug was found to be labile to oxidative stress condition. The amount of drug remaining after heating at 40 C for 8 h in 10% H 2 O 2 was 59.10%. In order to study the effect of stress conditions, heating at 80 C for 4 h in 30% H 2 O 2 was carried out with 53.97% of drug degradation. The HPLC analysis indicated the presence of a degraded product peak with the reduction in the area of the drug peak (Figure 8 ).
The peaks at RT 2.617 and 3.642 min were found to be of major degradation products after heating for 4 h at 80 C in 30% H 2 O 2 . The shorter retention time of degraded products indicate different polarity or lower molecular mass as compare to lornoxicam. For milder conditions the drug showed no degradation.
When lornoxicam was heated with 30% H 2 O 2 for 4 h, degradation products of lornoxicam could be isolated and identified from the reaction mixture. The assignments of the dried precipitates of the degradation products as LOX 1 and LOX 2 ( Figure 6 ) were based on the comparison of the IR, NMR and mass spectral (m/z 292.7 and 209.8) data of intact lornoxicam with those of the purified degraded sample, separated from the degradation reaction.
The IR spectrum (KBr) of lornoxicam was characterized by the absorption frequency of C=O carbonyl band at 1655 cm -1 . On the other hand, the IR spectrum (KBr) of LOX 1 and LOX 2 showed the characteristic carbonyl band ( Figure 9 ). The NMR spectrum of LOX 1 in DMSO-2d6 was characterized by the appearance of the protons of methyl groups at  1.312 ppm (singlet, 3H, CH 3 ), protons of aromatic NH at  5.1 ppm (doublet, 2H, NH). Alcohol protons and protons of -CH 2 group were at  3.175 and 2.375 ppm (triplet, 1H, OH and singlet, 1H, CH). The NMR data is shown in Table 9 .
The NMR spectrum of LOX 2 in DMSO-2d6 was characterized by the appearance of the protons of methylene groups at  1.312 ppm (triplet, 2H, CH 2 ), protons of aromatic NH at  5.1 ppm (triplet, 1H, NH). The protons of -CH 2 group were at  2.375 ppm (singlet, 1H, CH). Figure 9 . The IR spectra of lornoxicam degredation product after peroxide degradation. ) occurred in minute amount. The oxidative stress would normally be the favored process leads to the formation of LOX 1 and LOX 2 ( Figure 6 ). The fragmentation pattern of the degradation product is shown in Table 10 .
After thorough comparison and interpretation of the LC-UV, IR, NMR and mass spectra of both the lornoxicam and of LOX 1 and LOX 2 , we can conclude that the degradation product LOX 1 eluted at about 2.617 min and LOX 2 eluted at about 3.642 min and gave the molecular ion peak at m/z ratio 292.7 and 209.8, while the molecular ion peak of lornoxicam was at m/z ratio 371.81 and elutes at 8.192 min.
Neutral conditions
The drug was found to be stable to the neutral water hydrolysis without any reduction in the drug peak area. No degradation of the drug was observed on heating initially at 25 C for 30 min and then for 2 h, then at 80 C for 4 h with water.
Thermal degradation studies
Lornoxicam was stable in both solution and solid state under thermal stress conditions. No degradation of the drug was observed when solution of the drug was kept at 70 °C for 15 days.
Photodegradation studies
Lornoxicam was found to be stable in all solution forms as well as in solid state to light, both in wrapped and unwrapped samples after exposure equivalent to ICH dose of light.
CONCLUSION
The developed HPLC technique is precise, specific, accurate and stability indicating. The developed method was validated based on ICH guidelines [18] . Statistical analysis proves that the method is repeatable and selective for the analysis of paracetamol and lornoxicam as bulk drug and in pharmaceutical formulations.
The method can be used to determine the purity of the drug available from the various sources by detecting the related impurities. It may be extended to study the degradation kinetics of lornoxicam and for its estimation in plasma and other biological fluids. As the method separates the drug from its degradation products, it can be employed as a stability indicating one. 
